arrow
G

George Giotopoulos

University of Cambridge
H指数:24
被引数:3,788

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Pharmacological inhibition of METTL1 as a therapy against solid and blood cancers

METTL1的药理学抑制作为对抗实体瘤和血液癌的疗法

Nature
IF48.5
2026-10-280
OAAI
A step-wise, deterministic and fatal mouse model of myeloid neoplasm with spontaneous acquisition of patient-relevant RTK–RAS mutations

分步、确定性且致命的小鼠髓系肿瘤模型,可自发获得与患者相关的RTK–RAS突变

2026-09-040
OA
The RNA helicase domain of NAT10 promotes the biogenesis of hypomodified ribosomes to enhance cancer cell proliferation

NAT10的RNA解旋酶结构域通过促进低修饰核糖体的生物发生来增强癌细胞增殖

2026-08-080
OA
Post-transcriptional depletion of ribosome biogenesis factors engenders therapeutic vulnerabilities in NPM1-mutant AML

转录后耗竭核糖体生物发生因子在NPM1突变AML中产生治疗易感性

Blood
IF23.1
2025-06-270
OA
CREBBP inactivation sensitizes B cell acute lymphoblastic leukemia to ferroptotic cell death upon BCL2 inhibition

CREBBP失活会增强B细胞急性淋巴细胞白血病在BCL2抑制下的铁死亡敏感性。

2025-05-200
OA
Treatment of acute myeloid leukemia models by targeting a cell surface RNA-binding protein

通过靶向细胞表面RNA结合蛋白对急性髓系白血病模型的治疗

2025-04-230
OA
Mitochondrial metabolism sustains DNMT3A-R882-mutant clonal haematopoiesis

线粒体代谢维持DNMT3A-R882突变性克隆性造血

NATURE
IF48.5
2025-04-161
PRE
Acute Resistance to BET Inhibitors Remodels Compensatory Transcriptional Programs Via p300 Co-Activation

急性对BET抑制剂的耐药性通过p300协同激活重塑补偿性转录程序

BLOOD
IF23.1
2024-11-050
PRE
Preleukemic single-cell landscapes reveal mutation-specific mechanisms and gene programs predictive of AML patient outcomes
2023-12-011
OAAI
Mannose metabolism inhibition sensitizes acute myeloid leukaemia cells to therapy by driving ferroptotic cell death
2023-04-148
OAAI
Sequential inverse dysregulation of the RNA helicases DDX3X and DDX3Y facilitates MYC-driven lymphomagenesis
2021-10-0149
OA
Mutational synergy during leukemia induction remodels chromatin accessibility, histone modifications and three-dimensional DNA topology to alter gene expression
2021-09-2323
OAAI
Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML
2019-03-1993
OAAI
Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors
2017-08-2154
OA